Gamma-aminobutyric acid type A (GABA-A) and Glutamate receptors (GluR) (GABA-A/GluR)

This entry refers to a combination of two distinct and primary neurotransmitter systems: the inhibitory Gamma-aminobutyric acid type A (GABA-A) receptors and the excitatory Glutamate receptors. GABA-A receptors are pentameric ligand-gated ion channels that conduct chloride ions to hyperpolarize neurons, thereby mediating fast inhibitory neurotransmission (Sigel & Steinmann, 2012). Glutamate receptors include ionotropic types (NMDA, AMPA, and Kainate) and metabotropic types (mGluRs), which together mediate the majority of excitatory signaling and synaptic plasticity in the brain (Traynelis et al., 2010). The functional interplay between these systems, known as the excitation-inhibition (E/I) balance, is essential for maintaining neural homeostasis and cognitive function (Sohal & Rubenstein, 2019). Dysregulation of this balance is a hallmark of various neurological and psychiatric conditions, including epilepsy, anxiety, and schizophrenia (Olsen, 2018). Pharmacological modulation of these receptors is a cornerstone of CNS therapy, utilizing GABA-A positive allosteric modulators like benzodiazepines for sedation and anticonvulsant effects, or glutamate receptor modulators like memantine for neuroprotection (Niswender & Conn, 2010). Therapeutic development in this area remains challenging due to the ubiquitous expression of these receptors, which can lead to significant side effects like sedation or cognitive impairment. Because this entry groups two separate receptor families with opposing physiological roles, it is considered a composite rather than a single therapeutic target.

Other names

GABA-A receptorsGlutamate receptorsIonotropic neurotransmitter receptorsExcitatory and inhibitory receptors

Positive allosteric modulation of GABA-A receptors; Antagonism of NMDA and AMPA ionotropic glutamate receptors; Modulation of metabotropic glutamate receptors.